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ABSTRACT
Cytochrome P450 (CYP) is a heme protein oxidizing various xenobiotics, as well as endogenous substrates. Understanding which 
CYP enzymes are involved in metabolic activation and/or detoxication of different compounds is important in the assessment of an 
individual’s susceptibility to the toxic action of these substances. Therefore, investigation which of several in vitro experimental models 
are appropriate to mimic metabolism of xenobiotics in organisms is the major challenge for research of many laboratories. The aim of 
this study was to evaluate the efficiency of different in vitro systems containing individual enzymes of the mixed-function monooxy-
genase system to oxidize two model substrates of CYP3A enzymes, exogenous and endogenous compounds, α-naphtoflavone (α-NF) 
and testosterone, respectively. Several different enzymatic systems containing CYP3A enzymes were utilized in the study: (i) human 
hepatic microsomes rich in CYP3A4, (ii) hepatic microsomes of rabbits treated with a CYP3A6 inducer, rifampicine, (iii) microsomes of 
Baculovirus transfected insect cells containing recombinant human CYP3A4 and NADPH:CYP reductase with or without cytochrome 
b5 (Supersomes™), (iv) membranes isolated from of Escherichia coli, containing recombinant human CYP3A4 and cytochrome b5, and 
(v) purified human CYP3A4 or rabbit CYP3A6 reconstituted with NADPH:CYP reductase with or without cytochrome b5 in liposomes. 
The most efficient systems oxidizing both compounds were Supersomes™ containing human CYP3A4 and cytochrome b5. The 
results presented in this study demonstrate the suitability of the supersomal CYP3A4 systems for studies investigating oxidation of 
testosterone and α-NF in vitro. 
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1994). CYP3A enzymes are induced by rifampicin (RIF) in 
the human (CYP3A4/5) and rabbit (CYP3A6), but not in 
rat (CYP3A1/2). CYP3A4 demonstrates homotropic coop-
erativity (non-Michaelis-Menten kinetics) with a number 
of substrates (Atkins 2005, Ekins et al., 2003, Guengerich 
1999, Tsalkova et al., 2007, Ueng et al., 1997). The enzyme 
is also known to exhibit heterotropic cooperativity, which is 
characterized by increased oxidation of one substrate in the 
presence of an effector, such as α-naphthoflavone (α-NF), 
that may also serve as a substrate or inhibitor (Galetin et al., 
2002, Harlow and Halpert 1998, Koley et al., 1997, Shou et al., 
1994, Tang and Stearns 2001, Tsalkova et al., 2007). During 
the past decade understanding of the mechanism of CYP3A4 
cooperativity has progressed from a static model with mul-
tiple binding sites (Domanski et al., 1998, Shou et al., 1994, 
Tsalkova et al., 2007, Ueng et al., 1997) to more complex 
dynamic model suggesting effector-induced conformational 
rearrangements of the enzyme along with multiple ligand 
binding (Atkins et al., 2001, Isin and Guengerich 2006).
CYP3A4 cooperativity may be influenced by the levels 
of the redox partners, such as cytochrome b5 or cumene 
hydroperoxide, relative to the CYP (Kumar et al., 2005, 
Ueng et al., 1997). Cytochrome b5 has been reported to 
stimulate CYP3A4, dependent on the specific substrate 
(Kumar et al., 2005, Patki et al., 2003, Yamazaki et al., 1999). 
IntroDuctIon
The cytochrome P450s (CYP) are a family of hemoprotein 
enzymes that play important roles in the metabolism of 
drugs and carcinogens, as well as endogenous compounds 
such as prostaglandins, fatty acids and steroids (Gonzalez 
and Gelboin, 1992, Ortiz de Montellano 1995). 
CYP3A is one of the major subfamilies expressed in 
human livers and is found at high levels in the intestinal 
tract (Hosea et al., 2000). This enzyme oxidizes endogenous 
and exogeneous compounds as well as over half of the drugs 
in therapeutic use (Hosea et al., 2000). The human CYP3A 
subfamily expressed in human livers consists of CYP3A4 
(Beaune et al., 1986), CYP3A5 (Aoyama et al., 1989, Yamaori 
et al., 2003), and CYP3A7 (Kitada et al., 1985, Yamaori et al., 
2003). CYP3A4 is the most abundant form of CYP3A (~30% 
of total CYP) expressed in adult human livers (Shimada et al., 
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The mode of action of cytochrome b5 remains controversial 
(Kumar et al., 2005). Although the role of this protein as a 
source of electrons for CYPs is well known (Guryev et al., 
2001, Schenkman and Jansson 1999, Yamazaki et al., 2001), 
increasing evidence points to an allosteric effects of cyto-
chrome b5 mediated in part by an effect on the CYP spin 
state (Reed and Hollenberg 2003a, Reed and Hollenberg 
2003b). Its modulatory effect is further supported by the 
fact that cytochrome b5 not only increases CYP activity but 
in some cases also inhibits its activity (Reed and Hollenberg 
2003b, Yamaori et al., 2003). In addition, the interaction 
with cytochrome b5 may affect the degree of oligomeriza-
tion of CYP in membrane (Yamada et al., 1995).
Understanding which CYP enzymes are involved in the 
metabolic activation and/or detoxication of xenobiotics and 
endogenous compounds is important in the assessment of 
an individual’s susceptibility to the toxic action of these 
substances. Therefore, investigation which of several in vitro 
experimental models are appropriate to mimic metabolism 
of  xenobiotics  in  organisms  is  the  major  challenge  for 
research of many laboratories.
The aim of the present work was to evaluate the effi-
ciency of different in vitro systems containing individual 
enzymes of the mixed-function monooxygenase system to 
oxidize two model substrates of CYP3A, exogenous (α-NF) 
and endogenous (testosterone) compounds, respectively. 
MaterIalS anD MethoDS
Chemicals
Glucose-6-phosphate, NADP+, NADPH, α-NF, 3-[(3-chol-
amidopropyl)dimethyl-ammonio]-1-propane  sulfonate 
(CHAPS), dilauroyl phosphatidylcholine, and dithiothreitol 
were obtained from Sigma Chemical Co. (St. Louis, MO, 
USA).  Testosterone  and  6β-hydroxytestosterone  were 
purchased from Merck (Darmstadt, Germany). Glucose-
6-phosphate dehydrogenase was from Serva (Heidelberg, 
Germany). Bicinchoninic acid was from Pierce (Rockford, 
IL, USA). All chemicals were of a reagent grade or better.
Animals and pretreatment
Adult  male  rabbits  (2.5–3.0 kg,  VELAZ,  The  Czech 
Republic) were fed ad libitum on pellet chow and water one 
week before treatment. Then, rabbits were pretreated with 
RIF (50 mg/kg in 40 mM NaOH i.p. for 3 consecutive days) 
and used for isolation of microsomes.
Preparation of microsomes, isolation of enzymes and assays
Microsomes were isolated from livers of rabbits pretreated 
with RIF as described previously (Stiborova et al., 1995, 
Stiborova et al., 1990) and stored in 0.5 ml aliquots in 
liquid nitrogen until use. CYP3A6 was isolated from liver 
microsomes of rabbit induced by RIF. The procedure was 
analogous as described previously (Haugen and Coon 1976, 
Yang et al., 1985). Rabbit liver NADPH:CYP reductase was 
purified as described earlier (Yasukochi et al., 1979). Protein 
concentrations  were  assessed  using  the  bicinchoninic 
acid  protein  assay  with  serum  albumin  as  a  standard 
(Wiechelman et al., 1988). Total CYP content was measured 
based on complex of reduced CYP with CO (Omura and 
Sato 1964). Supersomes™ were from Gentest corp. (Woburn, 
MA). Membranes isolated from of Escherichia coli, contain-
ing human CYP3A4 was a gift from Dr. Soucek (National 
Institute  of  Public  Health,  Prague,  Czech  Republic). 
Purified  human  CYP3A4  was  from  Prof.  Anzenbacher 
(Palacky University, Olomouc, Czech Republic) and human 
microsomes from Dr. Szotakova (Charles University, Hradec 
Kralove, Czech Republic).
Testosterone 6β-hydroxylation
The incubation mixtures for measuring the testosterone 
metabolism contained in a final volume of 0.5 ml: 0.1 M 
potassium  phosphate  buffer,  pH 7.4,  50 µM  testosterone 
(2 µl of stock methanol solution per incubation), 10 mM 
MgCl2,  10 mM  D-glucose  6-phosphate,  1 mM  NADP+, 
1 U/ml D-glucose 6-phosphate dehydrogenase and one from 
the used enzyme system: (i) human hepatic microsomes 
(0.2 µM CYP), (ii) hepatic microsomes of rabbits treated 
with  a  CYP3A6  inducer,  rifampicine  (0.2 µM  CYP)  , 
(iii) microsomes of Baculovirus transfected insect cells 
containing recombinant human CYP3A4 (0.05 µM) and 
NADPH:CYP reductase with or without cytochrome b5 
(0.2 µM) (Supersomes™), (iv) membranes isolated from of 
Escherichia coli, containing recombinant human CYP3A4 
(0.05 µM) and cytochrome b5 (0.2 µM) reconstituted with 
NADPH:CYP reductase (0.05 µM), and (v) purified human 
CYP3A4 (0.05 µM) or rabbit CYP3A6 (0.2 µM) reconsti-
tuted with NADPH:CYP reductase ( 0.05 or 0.2 µM) with 
or without cytochrome b5 (0.2 or 0.8 µM) in liposomes. 
Microsomes and Supersomes™ were diluted on the con-
centration mentioned above. Bacterial membranes were 
reconstituted 10 min with NADPH:CYP reductase and 
cytochrome b5 and then diluted with buffer on the used 
CYP concentration (see above). Reconstitution of purified 
CYP3A4 and CYP3A6 with NADPH:CYP reductase was 
carried out essentially as described earlier (Burke et al., 
1985). Briefly, CYP3A were reconstituted as follows (0.5 µM 
CYP3A, 0.5 µM NADPH:CYP reductase, 0.5 µg/µl CHAPS, 
0.1 µg/µl vesicles (from D,L-dilauroylphosphatidylcholine), 
3 mM reduced glutathione and 50 mM HEPES/KOH, pH 7.4). 
An aliquot containing 25 pmol of reconstituted CYP3A4 or 
100 pmol of reconstituted CYP3A6 was added to incubation 
mixtures. The mixtures were incubated for 15 min, at 37 °C 
in a shaking incubator. The reaction was terminated by addi-
tion of 0.1 ml of 1 M aqueous Na2CO3 containing 2 M NaCl. 
Then, phenacetin (5 µl of 1 mM stock solution) was added as 
an internal standard. The metabolites were extracted with 
2 ml of CH2Cl2 and the extracts were evaporated to dryness. 
The residues were dissolved in the mobile phase for HPLC 
(see below). 
HPLC conditions
Testosterone and its metabolites were separated on Nucleosil 
(C18) HPLC column (4.6 × 25 mM, 5 µm, Macherey-Nagel, 
Germany). The flow rates, mobile phases and detection 
wavelengths for assays were 0.6 ml/min, 70:30 CH3OH/H2O 
(v/v), and 254 nm, respectively.157
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Oxidation of α-NF
Incubation mixtures contained in a final volume of 0.5 ml: 
0.1 M potassium phosphate buffer, pH 7.4, 150 µM α-NF 
(2 µl  of  stock  methanol  solution  per  incubation),  50 µl 
of NADPH-generating system (see above) and the same 
enzyme systems as in the case of testosterone oxidation (see 
above). The mixtures were incubated for 30 min at 37 °C in a 
shaking incubator. The reaction was terminated by addition 
of 0.1 ml of 1 M aqueous Na2CO3 containing 2 M NaCl. The 
α-NF metabolites were extracted with 2 ml of CH2Cl2 and 
the extracts were evaporated to dryness. The residues were 
dissolved in the mobile phase for HPLC. Samples were ana-
lyzed by HPLC as described elsewhere (Hosea et al., 2000, 
Thakker et al., 1981) to identify α-NF oxidation products. 
Two metabolites with retention times of 13.0 and 21.0 min 
(Figure 2), which were previously assigned as the trans-7,8-
dihydrodiol and 5,6-epoxide were formed (Andries et al., 
1990, Hosea et al., 2000, Shou et al., 1994). Mass spectros-
copy  (MALDI-TOF  using  α-cyano-4-hydroxycinnamic 
acid as a matrix) of the metabolite with a retention time 
of 13.0 min gave molecular ions at m/z 307 (M+H)+ and 
m/z 329 (M+Na)+, suggesting a dihydrodiol derivative. The 
metabolite with a retention time of 21.0 min gave molecular 
ions at m/z 289 (M+H)+ and m/z 311 (M+Na)+ and peaks at 
m/z 273 (M+H)+ and at m/z 295 (M+Na)+, that is an indica-
tive of an epoxide metabolite. The results are consistent 
with a previous studies on the metabolism of α-NF by rat 
microsomes pretreated with 3-methylcholanthere (Andries 
et al., 1990) and by purified reconstituted CYP3A4 (Shou 
et al. 1994), in which these two metabolites were identified 
as  trans-7,8-dihydrodiol  (retention  time = 13.0 min)  and 
5,6-epoxide  (retention  time = 21.0 min).  Another minor 
metabolite eluted with retention time of 9.6 min has not been 
identified yet (Figure 2). Two peaks eluted with retention 
times of 26.6 and 28.2 min seem not to be the products of 
α-NF oxidation, because they are also present in the control 
reaction samples. These samples containing all reaction 
components were immediately (without incubation) applied 
on a HPLC column to analyze. 
reSultS
Several different systems containing CYP3A enzymes were 
utilized to investigate oxidation of testosterone and α-NF 
in vitro: (i) human hepatic microsomes rich in CYP3A4, (ii) 
hepatic microsomes of rabbit treated with CYP3A6 inducer, 
rifampicine, (iii) microsomes of Baculovirus transfected 
insect cells containing recombinant human CYP3A4 and 
NADPH:CYP reductase with or without cytochrome b5 
(Supersomes™), (iv) membranes isolated from of Escherichia 
coli, containing human CYP3A4 with or without cytochrome 
b5, and (v) purified human CYP3A4 or rabbit CYP3A6 
reconstituted with NADPH:CYP reductase with or without 
cytochrome b5 in liposomes.
The most efficient systems oxidizing testosterone to its 
6β-hydroxylated metabolite were Supersomes™ containing 
human CYP3A4 and cytochrome b5 (Figure 1), while low effi-
ciency of CYP3A4 and/or CYP3A6 expressed in membranes 
of E. coli or reconstituted with NADPH:CYP reductase in 
liposomes were found (Figure 1). The activity of purified 
CYP3A4  or  CYP3A6  reconstituted  with  NADPH:CYP 
reductase (measured as testosterone 6β-hydroxylation) was 
enhanced by cytochrome b5. This protein did not influence 
oxidation of testosterone by recombinant CYP3A4 of E.coli 
membranes.
α-NF was oxidized into two metabolites, tentatively iden-
tified as trans-7,8-dihydrodiol (retention time = 13.0 min) 
and 5,6-epoxide (retention time = 21.0 min) by mass spectra 
and previously reported data (Andries et al., 1990, Shou et al., 
1994) (Figure 2). Under the condition used, 5,6-epoxide was 
the major product in all systems used. The most efficient 
system oxidizing α-NF was Supersomes™ containing human 
CYP3A4 and cytochrome b5 (Figure 3). Also low efficiency 
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Figure 1. 6β-Hydroxylation of testosterone by enzymatic systems 
containing CYP3A4 or CYP3A6.
Figure 2. HPLC separation of α-NF metabolites by HPLC formed by 
incubations  of  150 μM  α-NF  with  human  microsomes  (100 pmol 
CYP) and NADPH-generating system. See Materials and Methods for 
details. 7,8-dihydrodiol, 5,6-epoxide and unknown metabolite were 
found. Peaks assigned as K are present also in control incubations 
without NADPH-generating system. Phenacetin was used as an inter-
nal standard. 158
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of CYP3A4 and/or CYP3A6 expressed in membranes of E. 
coli or reconstituted with NADPH:CYP reductase in lipo-
somes to oxidize α-NF were found (Figure 3). Their activity 
was enhanced by cytochrome b5, while cytochrome b5 did 
not influence α-NF oxidation by recombinant CYP3A4 of 
E.coli membranes. 
Surprisingly, although 6β-hydroxylation of testosterone 
catalyzed by recombinant human CYP3A4 and NADPH:CYP 
reductase without cytochrome b5 in Supersomes™ was very 
effective, α-NF oxidation was low in this system (Figures 1 
and 3).
DIScuSSIon
In this report we evaluated CYP3A activity in different 
enzymatic systems (microsomal and/or reconstituted sys-
tems). Under the condition used, the most efficient systems 
oxidizing testosterone to its 6β-hydroxylated metabolite 
and  α-NF  to  trans  7,8-dihydrodiol-  and  5,6-epoxide 
were  Supersomes™  containing  human  CYP3A4  and 
cytochrome b5. It has been shown that some CYP3A4 
activities are dependent on cytochrome b5, specific lipid 
mixtures, cholate, buffer and salt composition (Shimada 
and Yamazaki 1998, Yamazaki et al., 1996).The results of 
this study clearly show that the effect of cytochrome b5 on 
CYP3A4-mediated oxidation of testosterone was different 
from that on oxidation of α-NF. This protein seems to be 
essential for the effective conversion of α-NF to its metabo-
lites. Namely, 6β-hydroxylation of testosterone catalyzed by 
recombinant human CYP3A4 and NADPH:CYP reductase 
in Supersomes™ was effective even without cytochrome b5. 
On the contrary α-NF oxidation by this enzymatic system 
was negligible without cytochrome b5. 
The results presented in this study demonstrate the 
suitability of the supersomal CYP3A4 systems for studies 
investigating oxidation of testosterone and α-NF in vitro. 
The  data  indicate  that  results  found  in  a  variety  of 
studies employing different enzymatic systems to evaluate 
the degree of participation of individual CYP enzymes in 
xenobiotic  metabolism  should  be  carefully  interpreted. 
In order to properly evaluate a role of individual CYPs in 
metabolism, combination of various in vitro and in vivo 
approaches should be utilized.
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Figure 3. α-NF oxidation by enzymatic systems containing CYP3A4 
or CYP3A6.
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